Aeglea BioTherapeutics Announces Achievement Of Primary Endpoint In Phase 3 Study Of Pegzilarginase In Patients With Arginase 1 Deficiency; Co. Reports ‘80% plasma arginine reduction (primary endpoint; p<0.0001) accompanied by a positive trend in GMFM-E'

by | Dec 6, 2021 | Extra Jobs | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.